Reto Wittwer
Finanzdirektor/CFO bei Cardiorentis AG
Aktive Positionen von Reto Wittwer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cardiorentis AG
 Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Finanzdirektor/CFO | 10.01.2016 | - |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Direktor/Vorstandsmitglied | - | - |
| Finanzdirektor/CFO | - | - |
Karriereverlauf von Reto Wittwer
Ausbildung von Reto Wittwer
| University of St. Gallen | Graduate Degree |
| University of Zurich | Graduate Degree |
Statistik
International
| Schweiz | 5 |
Operativ
| Director of Finance/CFO | 2 |
| Graduate Degree | 2 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cardiorentis AG
Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
- Börse
- Insiders
- Reto Wittwer
- Erfahrung
